Next generation of targeted dendritic cell vaccines for cancer treatment
| Reference number | |
| Coordinator | 3H Biomedical AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | October 2018 - March 2019 |
| Status | Completed |
Purpose and goal
3H Biomedical has developed the next generation of targeted dendritic cell vaccines for cancer treatment.
Expected results and effects
We have built comprehensive experimental data, a vaccine development roadmap that contains a time based path through the entire development of the drug candidate from early stage pre-clinical studies to clinical trials.
Planned approach and implementation
1.We will improve and validate the production process of new drug candidates in human cells: DONE 2.We will study the functionality and effect of new drug candidates in preclinical experiments: DONE 3.Strengthen IP position: DONE 4.Seek collaboration with branch experts and pharma companies for drug development: DONE 5.Business plan consolidation to attract collaboration: DONE